
Brendah K Masisi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2861685/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in estrogen receptor-positive breast cancer. Breast Cancer Research and Treatment, 2021, 189, 317-331.	2.5	5
2	The Biological and Clinical Significance of Glutaminase in Luminal Breast Cancer. Cancers, 2021, 13, 3963.	3.7	8
3	The role of glutaminase in cancer. Histopathology, 2020, 76, 498-508.	2.9	101
4	PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer. BMC Cancer, 2020, 20, 425.	2.6	10
5	Integrated Analysis of Key Differentially Expressed Genes Identifies DBN1 as a Predictive Marker of Response to Endocrine Therapy in Luminal Breast Cancer. Cancers, 2020, 12, 1549.	3.7	7
6	The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer. Breast Cancer Research and Treatment, 2020, 181, 1-12.	2.5	12
7	Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer. International Journal of Molecular Sciences, 2020, 21, 1407.	4.1	24
8	CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy. Breast Cancer Research and Treatment, 2019, 178, 535-544.	2.5	36
9	Glutamate dehydrogenase (GLUD1) expression in breast cancer. Breast Cancer Research and Treatment, 2019, 174, 79-91.	2.5	32